What is Oncopole?
Oncopole is a Quebec-based entity dedicated to accelerating the fight against cancer through research, development, and strategic investment. Positioned as a hub for innovation, the company aims to foster collaboration and drive progress in oncology, leveraging substantial enterprise-level funding to achieve its ambitious goals.
How much funding has Oncopole raised?
Oncopole has raised a total of $5.5M across 1 funding round:
Other Financing Round
$5.5M
Other Financing Round (2023): $5.5M with participation from Merck & Co, Pfizer, and GSK
Key Investors in Oncopole
Merck & Co
Merck & Co., a global healthcare company founded in 1891, delivers innovative solutions through prescription medicines, biologic therapies, vaccines, and animal health products.
Pfizer
Pfizer is a biopharmaceutical company focused on researching, developing, manufacturing, and marketing medicines and vaccines across multiple therapeutic areas, including oncology.
GSK
GSK plc is a British multinational pharmaceutical and biotechnology company with a research and development focus on oncology, immunology, and infectious diseases, aiming to positively impact global health.
What's next for Oncopole?
The recent major strategic investment signals a new phase of growth and expansion for Oncopole. This capital infusion is expected to fuel further research initiatives, bolster development pipelines, and potentially broaden the company's impact within the global fight against cancer. The focus on strategic backing suggests a trajectory towards scaling operations and solidifying its position as a key player in the biotech and healthcare investment landscape.
See full Oncopole company page
